Table 4.
Associations between patients and treatment characteristics and seizures
| Covariate | N with seizures/N all patients | % at 20 years (95% CI) | Hazard ratio (95% CI) | p-value |
|---|---|---|---|---|
| Protocol | < 0.001 | |||
| 58741 | 23/50 | 45.0 (32.9–61.6) | 1 | |
| 58831/2 | 27/189 | 13.3 (9.3–19.2) | 0.29 (0.16–0.51) | |
| 58881 | 45/596 | 7.8 (5.9–10.3) | 0.15 (0.09–0.25) | |
| Age at diagnosis, years | 0.099* | |||
| < 6 | 53/549 | 9.6 (7.4–12.5) | 1 | |
| 6–9 | 29/168 | 17.5 (12.3–24.8) | 1.67 (1.04–2.66)* | |
| 10–17 | 13/118 | 10.3 (6.0–17.5) | 1.10 (0.60–2.04)* | |
| CNS involvement at diagnosis | 0.079* | |||
| No CNS involvement | 86/785 | 10.8 (8.8–13.3) | 1 | |
| CNS involvement | 8/44 | 18.3 (9.8–34.2) | 1.95 (0.93–4.09)* | |
| VHR after consolidation** | 0.143 | |||
| Not VHR | 37/535 | 7.2 (5.3–9.8) | 1 | |
| VHR | 6/46 | 13.2 (6.3–27.9) | 1.90 (0.80–4.47) | |
| Randomized HD Cytarabine** *** | ||||
| No HD Cytarabine | 5/97 | 5.3 (2.2–12.4) | ||
| HD Cytarabine | 7/94 | 7.7 (3.8–15.7) | ||
CNS, central nervous system; HD Cytarabine, high-dose cytarabine; VHR, very high risk
*Adjusted for protocol
**Based on the 58881 study only
***A formal comparison using the Fine and Gray model was not performed due to the small number of events